gdc
ImmunotherapyLeukemiaLymphomaPersonalized Medicine

Telling Patients About CAR T-Cell Therapy

Nurse Navigator Claire White describes the way she tells her patients what CAR T-cell therapy is and how it works.
Video Library – March 6, 2019
Claire White, BSN, RN, CPHON
The Children's Hospital of Philadelphia, Philadelphia, PA
Nurse Navigator Claire White describes the way she tells her patients what CAR T-cell therapy is and how it works.
Recommended For You
FDA Approvals, News & UpdatesLeukemia
First-Line Treatment with Calquence Produces Long-Term Responses in Patients with Chronic Lymphocytic Leukemia
By Dana Taylor
The FDA approved a new Bruton tyrosine kinase (or BTK), Calquence, for first-line treatment of patients with CLL.
Leukemia
Treatment of CLL Should Be Determined by the Patient’s Risk Level

The results of a new longitudinal study should help to dispel the belief that chronic lymphocytic leukemia (CLL) is an indolent (slow-growing) disease that only requires an active surveillance approach instead of active treatment.

Leukemia
Long-Term Safety and Efficacy of Acalabrutinib as First-Line Therapy in CLL
Long-term results of a pivotal trial of acalabrutinib verify that it is effective and safe as first-line therapy for patients with chronic lymphocytic leukemia.
Leukemia
Investigational CD20 Antibody, Ublituximab, plus Ibrutinib Shows Benefit in Phase 3 Study of Patients with CLL
According to findings from a large clinical trial, the combination of ibrutinib and ublituximab is effective in treating patients with chronic lymphocytic leukemia.
Last modified: March 25, 2019

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country